Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)
Status:
Terminated
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
Both of bortezomib and vorinostat have identified Phase II doses for pediatric and adult
patients of which no grade 4 dose limiting toxicities have been observed in prior studies.
The pre-clinical synergy of these 2 agents when used in combination along with the lack of
over-riding toxicities and different mechanisms of action provide strong rationale for a
clinical trial investigating bortezomib and vorinostat in combination. This trial will use
the identified Phase II dose which is at or below the maximum tolerated dose for both agents
which have very acceptable toxicity profiles and such should prove feasible and tolerable in
this relapsed/refractory ALL population.